[1] Bladder cancer is usually stratified into two broad categories: papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...

They are also anticipating submitting a supplemental application in the United States to extend approval to include patients with papillary bladder cancer, rather than just those patients with ...

Conclusions: High-grade noninvasive papillary bladder tumours are associated ... observed particularly in high grade urothelial bladder cancer clearly warrant subsequent studies on the potential ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

BCG unresponsive non-muscle invasive bladder cancer (NMIBC) in the papillary indication: Anticipated supplemental biologics license application (BLA) submission in 2025 Alternative source of BCG ...

The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors.

In April, the FDA approved Anktiva plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The arrangement will result in ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The drugmaker is seeking to have the therapy approved for the treatment of Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or ...

On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer ...